首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Intra- and Interlaboratory Agreement in Assessing the In Vitro Activity of Micafungin against Common and Rare Candida Species with the EUCAST CLSI and Etest Methods
【2h】

Intra- and Interlaboratory Agreement in Assessing the In Vitro Activity of Micafungin against Common and Rare Candida Species with the EUCAST CLSI and Etest Methods

机译:使用EUCASTCLSI和Etest方法评估米卡芬净对普通和稀有念珠菌物种的体外活性的实验室间和实验室间协议

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The emergence of resistant strains among common and rare Candida species necessitates continuous monitoring of the in vitro susceptibilities of those isolates. We therefore assessed the in vitro activities of micafungin against 1,099 molecularly identified isolates belonging to 5 common and 20 rare Candida species by the EUCAST, CLSI, and Etest methods, assessing both the intralaboratory agreement and the interlaboratory agreement for two centers. The median micafungin EUCAST MICs were as follows, from the lowest to the highest: for Candida albicans, 0.004 mg/liter; for C. glabrata, 0.016 mg/liter; for C. tropicalis, 0.031 mg/liter; for C. krusei, 0.125 mg/liter; for C. parapsilosis, 2 mg/liter. Among rare Candida species, high MICs were found for C. guilliermondii, C. lipolytica, C. orthopsilosis, C. metapsilosis, and C. fermentati. No resistant isolates were found by the CLSI method, whereas resistance rates of 1 to 2% were found by the EUCAST method. Overall, the EUCAST method resulted in MICs 1 to 2 dilutions higher than those found by the CLSI and Etest methods. The intra- and interlaboratory agreement between methods was >92%, except for the interlaboratory agreement between the EUCAST and CLSI methods (81%), where 17 to 31% of the differences were >2 2-fold dilutions for C. albicans, C. glabrata, C. tropicalis, and other rare Candida species and <6% for C. parapsilosis and C. krusei. For the other interlaboratory comparisons, the EUCAST method resulted in higher MICs than the Etest method for all species, but <7% of these differences were >2 2-fold dilutions. Overall, the CLSI method resulted in lower MICs than the Etest method, with 11% of all isolates demonstrating >2 2-fold-dilution differences (6 to 20% for C. albicans, C. tropicalis, and rare Candida species; <5% for C. glabrata, C. krusei, and C. parapsilosis) and smaller differences found after 24 h. Despite these differences, categorical agreement was excellent (>97%), with only 1 to 2% very major errors between the EUCAST method and the other two methods.
机译:在常见和稀有念珠菌种中出现抗药性菌株需要连续监测这些分离株的体外药敏性。因此,我们通过EUCAST,CLSI和Etest方法评估了米卡芬净对1099种分子鉴定的分离物的体外活性,这些分离物属于5个常见念珠菌和20种稀有念珠菌,同时评估了两个中心的实验室内协议和实验室间协议。米卡芬净EUCAST MIC的中位数如下,从最低到最高:白色念珠菌为0.004 mg /升;对于光滑念珠菌,0.016 mg /升;对于热带念珠菌,为0.031毫克/升;对于克鲁氏梭菌,为0.125 mg / L;对于副腿念珠菌,为2 mg / L。在稀有的念珠菌物种中,发现了瓜氏梭状芽胞杆菌,解脂梭状芽孢杆菌,直立弯曲菌,间质弯曲杆菌和发酵曲霉的高MIC。通过CLSI方法未发现抗性分离株,而通过EUCAST方法发现了1至2%的抗性率。总体而言,EUCAST方法产生的MIC比CLSI和Etest方法发现的MIC高1至2倍。方法之间的实验室间和实验室间一致性> 92%,除了EUCAST和CLSI方法之间的实验室间一致性(81%)外,其中17%至31%的差异是白色念珠菌的2倍稀释度,< em class =“ genus-species”> C。 glabrata C。 Tropicalis 和其他稀有的 Candida 物种,而 C的<6%。 C。克鲁斯。对于其他实验室间比较,对于所有物种,EUCAST方法产生的MIC均高于Etest方法,但这些差异中的<7%为> 2 2倍稀释度。总体而言,CLSI方法产生的MIC低于Etest方法,所有分离株中的11%表现出> 2倍稀释差异(白色念珠菌为6%至20% C。Tropicalis 和稀有的 Candida 物种; C。glabrata C。krusei C。parapsilosis )和24小时后发现较小的差异。尽管存在这些差异,但是类别一致性还是非常出色的(> 97%),EUCAST方法与其他两种方法之间只有1-2%的非常严重的错误。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号